UNITAID. AMDS Partners Meeting. UNITAID Strategy & 2013 Call for Letters of Intent. Brenda Waning. Page 1

Transcription

1 Page 1 UNITAID AMDS Partners Meeting UNITAID Strategy & 2013 Call for Letters of Intent Brenda Waning Geneva 7 May, 2013

2 UNITAID s Six Strategic Objectives SO1: Increase access to simple, point-of-care (POC) diagnostics for HIV/AIDS, TB, and malaria SO2: Increase access to affordable, adapted paediatric medicines to treat HIV/AIDS, TB, and malaria SO3: Increase access to emerging medicines and/or regimens, as well as new formulations, dosage forms, or strengths of existing medicines that will improve the treatment of HIV/AIDS and co-infections such as viral hepatitis SO4: Increase access to artemisinin-based combination therapies (ACTs) and emerging medicines, including paediatric formulations, that in combination with appropriate diagnostic testing will improve the treatment of malaria SO5: Secure supply of second-line TB medicines, and increase access to emerging medicines and regimens that will improve treatment of both drug-sensitive and multi drug-resistant TB SO6: Increase access to preventives for HIV/AIDS and malaria Page 2

3 Page 3 Determinants of Strategic Objectives (static) & Component Interventions (dynamic) Global Goals UNITAID Mission UNITAID Landscapes Six Strategic Objectives Component & Cross-cutting Interventions Mutually-supportive interventions combine to achieve each strategic objective Active Potential Exploratory

4 Page 4 HIV/AIDS Tuberculosis Malaria M = Medicines D = Diagnostics P = Preventives Availability Affordability Quality Acceptability/ Adaptability Delivery Market Dynamics Dashboard Distils all UNITAID s landscape analyses into single-page, visual summary. Facilitates ongoing discussion of issues across disease and product areas. Provides high-level context and rationale for areas of intervention considered ready (or near-ready) for UNITAID support. UNITAID MARKET DYNAMICS DASHBOARD (March 2013) DRAFT, NOT FOR CIRCULATION Current Market Shortcomings * Opportunity for Intervention*** M D P M D M D P PRODUCT TYPE ACCESS (Mar 2013) Composite severity of all current market shortcomings** (Mar 2013) Adult first-line 54% x x -- x x Low Current Over (Mar 2013) next 4 years Med - High Adult second-line ~30% x xx -- x xx Med High Paediatric 28% xx xx -- xx xx High High Viral hepatitis C co-infection TBD 1 x xx x xx xx Low Med CD4 <60% x xx xx x x Med- High Viral load (VL) <30% xx xx xx xx xx High High Early infant diagnosis (EID) Male circumcision devices Med <30% xx xx xx xx xx High High 10% of target x xx x -- xx Med Med Female condoms <1% -- xx -- xx xx Low Low Microbicides 0% xx xx -- Low Low Pre-exposure prophylaxis (PrEP) <1% xx xx Low Low Adult first-line 66% xx xx xx Low Med Adult second-line 19% 3 xx xx xx xx xx Med High Paediatric <50% 4 xx x xx xx xx High High Near-POC or POC Adult Paediatric Rapid diagnostic tests (RDTs) 40% 5 TB Dx 19% 6 MDR-TB Dx <5% DST x xx x xx x Med High <20% public <10% private 7 x xx xx x xx Med High <20% public <10% private 8 x xx xx xx xx Med High 77% public Minimal private x x xx x xx High High LLINs 21% xx x x x xx Low Med Indoor residual spraying (IRS) ~5% x xx -- x x Low Low

5 M = Medicines D = Diagnostics P = Preventives Page 5 Availability Affordability Quality Acceptability/ Adaptability Delivery Market Dynamics Dashboard (2) Dashboard elements in detail: Current Market Shortcomings * Opportunity for Intervention*** PRODUCT TYPE ACCESS (Mar 2013) Composite severity of all current market shortcomings** (Mar 2013) Current Over (Mar 2013) next 4 years % Access -- Minimal / not present x Moderate xx Severe Low Medium High Mild Moderate Moderatesevere Severe

6 Page 6 Purpose of Strategic Objectives Describe how UNITAID will contribute to the long-term goals of the global health community; they also act as: A clear statement of intent to achieve market and public health impact in key areas; An invitation to partners (including donors, implementers, industry, and country-level actors) to collaborate on specific efforts; and A signal to the market to orient availability, formulation, quality, pricing, and sustainable access to health products for HIV/AIDS and its co-infections, TB, and malaria in resource-limited settings.

7 Page Call for Letters of Intent (LOIs) "Open" Call for LOIs consistent with 6 strategic objectives While the call is "Open", there is great interest in LOIs for market interventions that improve access to medicines used in HIV, TB, and malaria: SO3: Increase access to emerging medicines and/or regimens, as well as new formulations, dosage forms, or strengths of existing medicines that will improve the treatment of HIV/AIDS and co-infections such as viral hepatitis SO4: Increase access to artemisinin-based combination therapies (ACTs) and emerging medicines, including paediatric formulations, that in combination with appropriate diagnostic testing will improve the treatment of malaria SO5: Secure supply of second-line TB medicines, and increase access to emerging medicines and regimens that will improve treatment of both drug-sensitive and multi drug-resistant TB

8 Page 8 Thank you Brenda Waning waningb@who.int